IN A MOVE to block generic over-the-counter (OTC) competition for its $3.2 billion antihistamine Claritin (loratadine) and lock-in sales of Clarinex (desloratadine), a newly launched successor, Schering-Plough Corp. (SHP) has filed separate suits against divisions of Johnson & Johnson (J&J) and American Home Products Corp. (AHP).
Clarinex does not contain a decongestant (that’s Clarinex-D) and therefore does not cause drowsiness. Clarinex is known as the first antihistamine to state in its labeling that grapefruit juice does not affect the absorption of the active ingredient.
FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.
|
